^
Association details:
| Biomarker: | ALK fusion + EML4-ALK variant 3 + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
Published date:
05/25/2023
Excerpt:
Pts with co-occurring EML4-ALK V3 and TP53 mutation had the shortest TTD (median TTD 8.7 [3.9–NR; HR: 2.59; P=0.0219]; Table).
DOI:
10.1200/JCO.2023.41.16_suppl.9029
Test:
